Read Larry Connors' blog – Short Term Trading Strategies
Researchers at the University of California, Los Angeles, and colleagues analyzed data from over two thousand women between the ages of forty-two to fifty-two who participated in the bone sub-study of the Study of Women's Health Across the Nation. The authors of the UCLA study also found premenopausal women and early perimenopausal women who had vasomotor symptoms were found to have lower femoral neck bone mineral density than those without vasomotor symptoms.
According to bone expert, Warren Levy, PhD, although the extent of correlation varied depending on the stage of menopause and the frequency of vasomotor symptoms, the findings did support earlier studies by others that have suggested an association between low estradiol levels, vasomotor symptoms, and low bone density.
"The concept of assessing bone health via the amount or intensity of hot flashes is interesting and may provide another method for screening for osteoporosis," suggests Dr. Levy, who is also CEO of Unigene Laboratories Inc., a biopharmaceutical company focused on peptide-based nasally and orally delivered osteoporosis treatments. "However, the gold standard today is a bone scan which is widely available and inexpensive for most patients. The study does help raise awareness about the importance of being vigilant about bone loss during this part of one's life, and encourages regular bone scans, if possible, because even early perimenopausal women can experience significant bone loss."
Some patients may opt to wait out their hot flashes so as not to take estrogen supplementation. "We hope that the new findings will encourage physicians and patients to also consider the various treatment options that are available without the use of estrogen-based products," says Dr. Levy, who believes that as life expectancy rates continue to rise, osteoporosis will have a greater impact on national health and quality of life. "If there are acceptable alternatives for patients with osteoporosis or low bone density, the side effect/safety profile of each drug should be considered carefully before treatment decisions are made." For more information, log on to www.unigene.com.
SOURCE: Unigene Laboratories Inc.
Unigene Laboratories Inc. Media: Janet Vasquez/IRG, 212-825 3210
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
